Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2007 Mar-Apr;27(2):1143-7.

The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.

Author information

1
Department of Orthopaedic Surgery, "METAXA" Cancer Hospital, Piraeus, Greece. markosioannou@yahoo.gr

Abstract

BACKGROUND:

Extra-abdominal desmoid tumors are rare neoplasms with variable biological behavior. The mainstay of treatment is surgery. Complementary treatment with tyrosine-kinase receptor inhibitor drugs, particularly imatinib mesylate, has been reported in the literature. The purpose of this study was to determine the possible presence of tyrosine-kinase receptors in extra-abdominal desmoid tumors as a marker for imatinib mesylate therapy.

PATIENTS AND METHODS:

From 1999 to 2004, immunohistochemical methods were carried-out in 14 patients with histologically confirmed extra-abdominal desmoid tumors to determine c-KIT positivity (existence of tyrosine-kinase receptors and PDGFRA and PDGFRB).

RESULTS:

All desmoid tumors were c-KIT negative, which demonstrates absence of tyrosine-kinase receptors.

CONCLUSION:

The histological c-KIT markup is an easy and reliable method that can detect whether a desmoid tumor is sensitive to additional treatment with a tyrosine-kinase receptor inhibitor. Molecular biological analysis for the identification of KIT and PDGFR mutation should be performed before imatinib mesylate is included in any treatment protocol.

PMID:
17465254
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center